Compound class:
Synthetic organic
Comment: AM1476 is a novel peripherally-acting serotonin 5‑HT2B receptor antagonist that was developed to reduce fibrosis-induced tissue damage and scarring. Example 49 in WO2016207231A1 represents the AM1476 racemate, and the hydrobromide formulation is example 50 [1].
|
|
No information available. |
Summary of Clinical Use |
AM1476 is a clinical candidate. It has been granted EU (EMA) and US (FDA) orphan designations for the treatment of skin and lung manifestations of systemic sclerosis. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04691115 | Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects | Phase 1 Interventional | AnaMar AB |